

PRESS RELEASE
For Immediate Distribution

Malaysian Genomics Inks Agreement in Expansion to Bangladesh

Group to cooperate with Toticell to distribute its products and services

PETALING JAYA, 15 MAY 2023 – **Malaysian Genomics Resource Centre Berhad** (“Malaysian Genomics” or “the Group”; Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, today announced a strategic cooperation agreement (“SCA”) with Toticell Limited (“Toticell”) for the distribution of the Group’s products in Bangladesh.

Toticell, which is based in Dhaka, Bangladesh, specialises in regenerative healthcare focusing on treatments for musculoskeletal conditions such as arthritis, sports-related injuries and tendinopathies.

Under the SCA, the parties agree to cooperate in the distribution of Malaysian Genomics’ cosmeceutical products, genetic screening tests, CAR T-cell therapy services, and other areas of mutual commercial interests.



Sasha Nordin, Chief Executive Officer of Malaysian Genomics ([Link](#))

Mr. Sasha Nordin, CEO of Malaysian Genomics said, “Bangladesh represents a market with vast opportunities given its population of approximately 165 million people. The country’s economy, which is the second-largest in South Asia, is growing rapidly it is identified by Goldman Sachs Inc. as one of the Next Eleven, along with the BRICS economies for potential. Malaysian Genomics is delighted to cooperate with Toticell to bring our products and services to Bangladesh.”



Azri Azerai, Executive Director of Malaysian Genomics ([Link](#))

Mr. Azri Azerai, Executive Director of Malaysian Genomics, said, “This collaboration with Toticell falls in line with Malaysian Genomics’ strategic expansion plan which includes diversifying geographically and globally.”

In April, MGRC announced that the Group has made progress in establishing partnerships following the signing of SCAs with several Dubai, United Arab Emirates (“UAE”) parties, namely American Spine Center (“ASC”), a Dubai, UAE-based specialist in spinal injury and spine pathology; BALSAM Health Services (“Balsam”), a Dubai, UAE-based healthcare service provider; Wellness by Design FZ LLC (“Wellness by Design”), a Dubai, UAE-based nutrition, obesity and weight loss specialist, and Sharjah, UAE-based IAC International LLC (“IAC”), which is coordinating and developing the partnerships.

MGRC also recently appointed Mr. Aswath Ramakrishnan as its new Independent Non-Executive Director. He is an experienced practising lawyer involved in commercial litigation, shipping and maritime, defamation, corporate and insolvency litigation, asset and debt recovery, intellectual property litigation, arbitration and cross-border dispute.

###

ABOUT MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD

Malaysian Genomics Resource Centre Berhad (“MGRC” or “the Group”) is a leading genomics and biopharmaceutical company based in Southeast Asia. The Group was established in 2004 and listed on the Bursa Malaysia stock exchange in 2010. From pioneering work in genome sequencing, bioinformatics analysis, and genetic screening services, MGRC has expanded into the biopharmaceutical sector with the manufacturing of cell therapies, including immunotherapy for various types of cancer.

Utilising its high-throughput sequencing lab, advanced microarray facility, and new state-of-the-art cell processing lab, the Group is committed to improving access to the latest in precision and personalised healthcare solutions to improve the lives of patients.

For more information, visit www.mgrc.com.my.

Issued By: Swan Consultancy Sdn. Bhd. on behalf of Malaysian Genomics Resource Centre Berhad

Date: 15 May 2023

For more information, please contact:

Jazzmin Wan

Tel: +60 17-289 4110

Email: j.wan@swanconsultancy.biz

Amida Baharim

Tel: +60 12-206 1209

Email: a.baharim@swanconsultancy.biz